Dr. Singh has more than 30 years of experience in the biotechnology field. He has a Ph.D. in Immunogenetics from the Max-Planck Institute, Germany. He had spent 11 years in academia, 10 months as a visiting scientist at Genentech before joining as Director of Cell and Molecular Biology at PharMingen, San Diego, CA. Soon after merger of PharMingen with Becton Dickinson, a fortune 500 company, Dr. Singh founded IMGENEX Corporation in 1997, which was sold to Novus Biologicals in 2013. Dr Singh’s vision is to establish a company whose mission is not only to develop high quality biomedical research tools for the characterization of these genes but also, through the discovery of novel therapeutically important genes, to develop indications for treatment of diseases.
He also started IMGENEX India Pvt. Ltd. in 2004 to provide affordable and high quality research tools to Indian scientist. IMGENEX India is a recipient of several grants from the Department of Biotechnology, India to develop nanotechnology based treatment of osteoporosis, to develop induced pluripotent stem cells, and to develop improved mammalian expression vector for production of therapeutic antibodies and recombinant proteins. He has over 60 papers in peer-reviewed journals and 3 US patents.